NFKB1 and cancer: Since NF-κB drives pathology by inducing tissue- and context-specific transcriptional programs, several research groups have pursued an alternative approach to overcome this barrier, i.e., targeting essential, specific effectors of NF-κB pathogenetic functions, including the promotion of cell survival, angiogenesis, inflammation, and metabolic adaptation, which are fundamental processes in a range of human disorders, including cancer [20,229] (Figure 5) (Table 1).